69 patents
Page 2 of 4
Utility
ANTI-CD38 Antibodies and Pharmaceutical Compositions Thereof for the Treatment of Autoantibody-mediated Autoimmune Disease
12 May 22
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease.
Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
Filed: 13 Mar 20
Utility
Antibodies Targeting C5AR
5 May 22
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR.
Julia NEUGEBAUER, Barbara BACHLER-KONETZKI, Tanja HERRMANN, Winfried ELLIS
Filed: 13 Mar 20
Utility
FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region
5 May 22
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region.
Julia NEUGEBAUER, Steffen RUNZ, Stefanie URLINGER
Filed: 10 Jan 22
Utility
Antibody Formulations
14 Apr 22
The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody.
Bodo BROCKS, Robert KELLERER
Filed: 13 Dec 19
Utility
Combinations and Uses Thereof
24 Mar 22
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
Filed: 8 Dec 21
Utility
Fab molecules with a rodent hinge region and a non-rodent CH1 region
22 Feb 22
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region.
Julia Neugebauer, Steffen Runz, Stefanie Urlinger
Filed: 13 Nov 17
Utility
Pharmaceutical Combinations for Treating Tumor Comprising ANTI-CD19 Antibody and Natural Killer Cell
17 Feb 22
Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same.
Jung Hyun HER, Mi Young JUNG, Su Hyun GWON, Ho Yong LIM, Sung Yoo CHO, Sung Yong WON, Yu Kyeong HWANG, Jan ENDELL, Rainer BOXHAMMER
Filed: 5 Sep 19
Utility
Multispecific Antigen-binding Molecules
10 Feb 22
Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
Andreas Bültmann, Karin Felderer, Sebastian Jäger, Steffen Runz, Johannes Urban
Filed: 4 Dec 19
Utility
Combinations and uses thereof
18 Jan 22
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jan Endell, Mark Winderlich, Rainer Boxhammer
Filed: 18 Aug 16
Utility
Anti-gm-csf Antibodies
11 Nov 21
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions.
Stefan STEIDL, Elisabeth THOMASSEN-WOLF
Filed: 7 May 21
Utility
Canine Antibody Libraries
14 Oct 21
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
Filed: 22 Apr 21
Utility
Treatment Paradigm for an ANTI-CD19 Antibody and Venetoclax Combination Treatment
23 Sep 21
The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
Peter Kelemen, Michael Schwarz, Mark Winderlich, Steffen Heeger, Dominika Weinelt
Filed: 30 May 18
Utility
GENERATION AND PROFILING OF FULLY HUMAN HuCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38
23 Sep 21
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions.
Michael TESAR, Ute JÄGER
Filed: 9 Jun 21
Utility
High Concentration Liquid Antibody Formulations
19 Aug 21
The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody.
Martin DOMNOWSKI, Roy EYLENSTEIN, Jan JAEHRLING, Daniel WEINFURTNER
Filed: 2 Jul 19
Utility
Polypeptide library
10 Aug 21
The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement.
Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
Filed: 8 Apr 20
Utility
Antibodies Targeting Glycoprotein VI
15 Jul 21
The present disclosure provides antibodies or antibody fragments specific for GPVI.
Kerstin UHLAND, Julia NEUGEBAUER, Steffen RUNZ
Filed: 15 May 19
Utility
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
13 Jul 21
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions.
Michael Tesar, Ute Jäger
Filed: 7 Sep 18
Utility
Nucleic acid encoding anti-GM-CSF antibodies
8 Jun 21
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions.
Stefan Steidl, Elisabeth Thomassen-Wolf
Filed: 17 Jun 19
Utility
Canine antibody libraries
25 May 21
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
Filed: 21 Jun 18
Utility
Treatment for Rheumatoid Arthritis
6 May 21
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis.
Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
Filed: 8 Jan 21